These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27778240)

  • 1. Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.
    Hatswell AJ; Freemantle N; Baio G
    Pharmacoeconomics; 2017 Feb; 35(2):163-176. PubMed ID: 27778240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.
    Anderson M; Naci H; Morrison D; Osipenko L; Mossialos E
    J Clin Epidemiol; 2019 Jan; 105():50-59. PubMed ID: 30236484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
    Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
    Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
    Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
    Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study.
    Lexchin J
    BMJ Open; 2018 Apr; 8(4):e020377. PubMed ID: 29705760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
    Erhel F; Scanff A; Naudet F
    Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation.
    Thurgar E; Barton S; Karner C; Edwards SJ
    Health Technol Assess; 2016 Mar; 20(24):v-vi, 1-486. PubMed ID: 27034016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.